Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin + Chemotherapy in Metastatic Pancreatic Adenocarcinoma
NCT02231723Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Aug 2014
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of napabucasin in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Adverse Events and Serious Adverse Events at 6 months and Recommended Phase 2 Dose at 3 months. Started Aug 2014; status: completed.
02
Drugs
napabucasin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02231723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231723.